Literature DB >> 2206568

The excess mortality rate. A useful concept in cancer epidemiology.

P Lenner1.   

Abstract

Death cause registers and cancer incidence registers are often used to elucidate progress (or lack of progress) in the battle against cancer. Trends in the age-adjusted mortality rate of cancer or of specific cancer types may thus mirror the overall effect of anticancer interventions (prevention, early diagnostics, treatment), but are often influenced by changes in the death cause diagnostics or in the coding routines at the registers. Relative survival rate (or its inversion, relative mortality rate) is sometimes used in order to elucidate improvement due to treatment. It is independent of the death cause diagnoses but often seriously influenced by changes in diagnostics of incident cancer; earlier diagnosis and increased detection of non-fatal cases may thus give an improved relative survival rate, quite unrelated to any improvement in the treatment. In the present paper the excess mortality rate is introduced as a measure which can give additional information concerning effects of anticancer interventions. In contrast to age-adjusted mortality rate it is not dependent on death cause diagnoses or coding routines, and in contrast to relative survival it is independent of the rate of non-fatal incident cancer cases.

Entities:  

Mesh:

Year:  1990        PMID: 2206568     DOI: 10.3109/02841869009090053

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  9 in total

1.  Trends in cancer incidence, survival and mortality in northern Sweden 1960-1986.

Authors:  P Lenner; H Jonsson; O Gardfjell
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

2.  Racial Disparities in Heart Disease Mortality in the 50 Largest U.S. Cities.

Authors:  Maureen R Benjamins; Jana L Hirschtick; Bijou R Hunt; Michelle M Hughes; Brittany Hunter
Journal:  J Racial Ethn Health Disparities       Date:  2016-12-06

3.  A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality.

Authors:  Marco Zappa; Donella Puliti; Jonas Hugosson; Fritz H Schröder; Pim J van Leeuwen; Ries Kranse; Anssi Auvinen; Sigrid Carlsson; Maciej Kwiatkowski; Vera Nelen; Alvaro Paez Borda; Monique J Roobol; Arnauld Villers
Journal:  Eur Urol       Date:  2014-01-07       Impact factor: 20.096

4.  Excess mortality associated with second hip fracture.

Authors:  B Sobolev; K J Sheehan; L Kuramoto; P Guy
Journal:  Osteoporos Int       Date:  2015-04-25       Impact factor: 4.507

5.  Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults.

Authors:  Ana C Xavier; Narendranath Epperla; Jeffrey W Taub; Luciano J Costa
Journal:  Am J Hematol       Date:  2017-11-21       Impact factor: 10.047

Review 6.  Trends in cancer survival and mortality rates.

Authors:  J Pontén; H O Adami; P Sparén
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

7.  Causes and predictors of mortality in Asian Indians with and without diabetes-10 year follow-up of the Chennai Urban Rural Epidemiology Study (CURES - 150).

Authors:  Ranjit Mohan Anjana; Ranjit Unnikrishnan; Poongkunran Mugilan; Padoor Sethuraman Jagdish; Balasubramanian Parthasarathy; Mohan Deepa; Geetha Loganathan; Rajendran Ashok Kumar; Thangarajan Rahulashankiruthiyayan; Ganesan Uma Sankari; Ulagamathesan Venkatesan; Viswanathan Mohan; Coimbatore Subramanian Shanthi Rani
Journal:  PLoS One       Date:  2018-07-09       Impact factor: 3.240

8.  A nationwide analysis of the excess death attributable to diabetes in Brazil.

Authors:  Paula A Bracco; Edward W Gregg; Deborah B Rolka; Maria Inês Schmidt; Sandhi M Barreto; Paulo A Lotufo; Isabela Bensenor; Dora Chor; Bruce B Duncan
Journal:  J Glob Health       Date:  2020-06       Impact factor: 4.413

9.  Cancer Incidence and Mortality in the Oldest Old: A Nationwide Study in Finland.

Authors:  Tomas Tanskanen; Karri J M Seppä; Anni Virtanen; Nea K Malila; Janne M Pitkäniemi
Journal:  Am J Epidemiol       Date:  2021-05-04       Impact factor: 4.897

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.